C.K. Ashok Kumar
Research Subjects
C.K. Ashok Kumar has a total of 6 co-authors. Here are the top co-authors by number of shared publications:
- Krishnaveni Manubolu
Narayana Pharmacy College, India
1 shared publication - Morla Devika1 shared publication
- Raveesha Peeriga
V.V. Institute of Pharmaceutical Sciences, India
1 shared publication - S. Mohana Lakshmi
Amity Institute of Pharmacy Amity University Bengaluru Bengaluru Karnataka India
1 shared publication - Saidatri Arige
Department of Pharmaceutical Analysis, V. V. Institute of Pharmaceutical Sciences, Gudlavalleru, Andhra Pradesh, India
1 shared publication - Vanukuri Lakshmana Vinod Kumar1 shared publication
Latest Publications
- 10 July 2025
- Published by Taylor & Francis
- p. 54-77
High Throughput Screening (HTS) and Phenotypic Screening
Modern drug discovery heavily depends on high-throughput screening (HTS) and phenotypic screening because they provide joint methods for therapeutic candidate identification and validation. The rapid automated technology system at HTS conducts tests on numerous compounds in volumes reaching thousands to millions to detect biological target responses. The use of target-based assays within this method achieves precise and scalable results, yet fails to show the complete effects of compounds on biological structures. The screening methodology in phenotypic testing determines compound efficacy through observable changes in cell or organismal phenotypes without needing target identification. The method proves crucial for identifying drug candidates which use fresh mechanisms of action among diseases whose pathways remain difficult to understand. Through their combination, HTS enables researchers to develop potent, stable drug candidates which successfully interact with biological systems at both target and system levels. Recent innovations such as artificial intelligence and 3D cell culture systems, and organ-on-a-chip technologies have improved both efficiency and prediction capabilities of screening strategies. Researchers can quicken the creation of effective therapeutics by combining methods synergistically through their drug discovery workflow.
- 10 July 2025
- Published by Taylor & Francis
- p. 54-77
High Throughput Screening (HTS) and Phenotypic Screening
Modern drug discovery heavily depends on high-throughput screening (HTS) and phenotypic screening because they provide joint methods for therapeutic candidate identification and validation. The rapid automated technology system at HTS conducts tests on numerous compounds in volumes reaching thousands to millions to detect biological target responses. The use of target-based assays within this method achieves precise and scalable results, yet fails to show the complete effects of compounds on biological structures. The screening methodology in phenotypic testing determines compound efficacy through observable changes in cell or organismal phenotypes without needing target identification. The method proves crucial for identifying drug candidates which use fresh mechanisms of action among diseases whose pathways remain difficult to understand. Through their combination, HTS enables researchers to develop potent, stable drug candidates which successfully interact with biological systems at both target and system levels. Recent innovations such as artificial intelligence and 3D cell culture systems, and organ-on-a-chip technologies have improved both efficiency and prediction capabilities of screening strategies. Researchers can quicken the creation of effective therapeutics by combining methods synergistically through their drug discovery workflow.
- 1 November 2024
- Published by Taylor & Francis
- p. 160-178
Lipid-Based Nanoparticles
Lipid-based nanocarriers have great potential to solubilize, encapsulate, and deliver active molecules in a programmed pattern to achieve desired bioavailability and avoid side effects. Nanocarrier-based delivery of phytochemicals exhibits enhanced aqueous solubility and bioavailability, specific tumor cell/tissue targeting, improved cellular uptake, reduced doses of phytochemicals, and steady-state therapeutic levels of the phytochemicals over an extended period of time while minimizing side effects and toxicity. In addition to that, it also shows excellent blood stability, multifunctional design of nanocarriers, and improvement in anticancer activities. Nanostructured lipid carriers (NLCs) provide the advantage of a controlled release system and have been increasingly developed as drug carriers in cancer treatments. PEG-conjugated NLCs escape from the capture of RES to circulate longer than conventional NLCs. NLCs are a second generation of lipid nanoparticles that consists of a mixture of solid and liquid lipids to create an imperfection on the crystal lattice, accommodating high drug load and enhanced penetration.
- 1 November 2024
- Published by Taylor & Francis
- p. 160-178
Lipid-Based Nanoparticles
Lipid-based nanocarriers have great potential to solubilize, encapsulate, and deliver active molecules in a programmed pattern to achieve desired bioavailability and avoid side effects. Nanocarrier-based delivery of phytochemicals exhibits enhanced aqueous solubility and bioavailability, specific tumor cell/tissue targeting, improved cellular uptake, reduced doses of phytochemicals, and steady-state therapeutic levels of the phytochemicals over an extended period of time while minimizing side effects and toxicity. In addition to that, it also shows excellent blood stability, multifunctional design of nanocarriers, and improvement in anticancer activities. Nanostructured lipid carriers (NLCs) provide the advantage of a controlled release system and have been increasingly developed as drug carriers in cancer treatments. PEG-conjugated NLCs escape from the capture of RES to circulate longer than conventional NLCs. NLCs are a second generation of lipid nanoparticles that consists of a mixture of solid and liquid lipids to create an imperfection on the crystal lattice, accommodating high drug load and enhanced penetration.